Posters

Prognostic factors for neovascular glaucoma in eyes with treated proliferative diabetic retinopathy

Poster Details

First Author: M.Lee SOUTH KOREA

Co Author(s):                                 

Abstract Details



Purpose:

To evaluate the factors that are significant for the progression to neovascular glaucoma in patients with proliferative diabetic retinopathy.

Setting:

Retrospective Analysis

Methods:

We reviewed the medical records of 52 patients who were first diagnosed with proliferative diabetic retinopathy from March 2014 to March 2016. We compared diabetes mellitus period, HbA1c, chronic diseases such as hypertension, hyperlipidemia and kidney disease etc, insulin treatments, blood urea nitrogen, blood creatinine, glomerular filtration rate, urine albumin, dialysis, corrected visual acuity at the first-visit, traction membrane sign of retina at the first-visit, vitreous haemorrhage and preretinal haemorrhage in each group and then investigated the prognostic factors of neovascular glaucoma.

Results:

A total of 52 patients were included in the investigation; of the 52 patients 12 patients (23.08%) were diagnosed with iris neovascularization and 4 patients (7.69%) developed neovascular glaucoma. The patients without iris neovascularization were defined as Group I, those with iris neovascularization as Group II, and those with neovascular glaucoma as Group III. The diabetes mellitus period was significantly longer in Group II (10.88±7.14 years) and in Group III (11.75±8.61 years) than Group I (8.30±5.25 years) (p-value 0.41, 0.032). The HbA1c level was 9.59±2.23 in Group II and 9.27±2.54 in Group I. There was no significant difference between the two groups. (P=0.721). But, HbA1c was significantly higher in Group III (11.55±0.21) than Group I (p-value 0.048).

Conclusions:

A long diabetes mellitus period and high HbA1c levels have a significant effect on the progression to neovascular glaucoma in patients with proliferative diabetic retinopathy, this information could be useful for predicting and preventing the prognosis of patients.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy